London, March 25, 2026, 15:06 GMT
Reckitt Benckiser hovered a bit over 5,100 pence on Wednesday, barely budging as the FTSE 100 added roughly 1.4%. Despite the small lift, shares remained more than 20% under their 6,514 pence high for the year.
That’s significant, with the stock still nursing wounds from a 6% slide on March 5—investors brushed off Reckitt’s fourth-quarter sales beat, focusing instead on a murky margin and profit outlook. The company, following peers like Unilever and Nestle, has been steering its portfolio toward brands with faster growth and fatter margins. “Emerging markets were absolutely a must-win set of markets for us,” CEO Kris Licht told Reuters. Still, Chris Beckett at Quilter Cheviot pointed out, some gains from the Essential Home sale are being eroded by currency swings and leftover costs. Reuters
Technically routine, Wednesday’s filings still drew investor attention in an uneasy market. Reckitt confirmed it had issued its 2025 annual report, along with the notice for its May 21 annual general meeting, and filed the paperwork with the National Storage Mechanism.
Support this time leaned on the buyback: Reckitt snapped up 156,500 shares on March 24, paying an average 5,100.08 pence each. Treasury shares now total 29.56 million. This round—up to 540 million pounds—marks the third slice of a 1 billion pound program.
Execution remains the focus for management. In its March update, Reckitt reported, “2025 has been a strong year with performance ahead of our expectations,” citing 5.2% underlying revenue growth for Core Reckitt and a 5.3% rise in adjusted operating profit. The company is sticking with its 2026 goal for core growth at 4% to 5%. Reckitt
Aarin Chiekrie, equity analyst at Hargreaves Lansdown, struck a more cautious note. Europe isn’t likely to show much strength in 2026, he said, and “investors will need patience”—Reckitt’s turnaround still has significant obstacles ahead. Hargreaves Lansdown
Here’s the bear case: Reckitt flagged weaker European sales and a lighter cold-and-flu season as headwinds heading into early 2026, while its filings confirm Mead Johnson faces its first federal court trial over U.S. infant formula in July 2026. If legal setbacks pile up or margin recovery drags, the real value of the buyback could come under pressure in a hurry.
Reckitt’s overhaul really kicked off last July, when the company struck a $4.8 billion deal to offload most of its Essential Home unit to Advent, hanging on to a 30% stake. Judging by Wednesday’s share price—just a shade over 5,100 pence—investors don’t seem ready to reward the leaner Reckitt just yet. They want to see consistent growth first.
